Back to Search
Start Over
Predictors of Long-Term Response With Pazopanib in Patients With Advanced Renal-Cell Carcinoma
- Source :
- Clinical Genitourinary Cancer. 16:293-297
- Publication Year :
- 2018
- Publisher :
- Elsevier BV, 2018.
-
Abstract
- Pazopanib is among the current standards of care for first-line treatment of patients with unresectable advanced renal-cell carcinoma (aRCC) or metastatic renal-cell carcinoma. This real-world study aimed to characterize those with long-term response to pazopanib in the treatment of aRCC in a community oncology setting, and to identify predictors of long-term response.aRCC patients treated with first-line pazopanib were classified as having long-term or non-long-term response (progression-free survival [PFS] of ≥ 18 or 18 months, respectively). Baseline patient demographics and clinical characteristics were evaluated and compared between the 2 groups. Differences in PFS and overall survival were also evaluated.A total of 153 eligible patients were identified, of which 33 (21.6%) and 120 (78.4%) patients were identified as having disease with long-term and non-long-term response, respectively. The median PFS for those with long-term response was 27.2 months (95% confidence interval [CI], 23.0-35.2) versus 6.9 months (95% CI, 5.0-8.6) for those with non-long-term response. Median overall survival was not reached (NR) for those with long-term response (95% CI, NR to 39.1) compared to 15.3 months (95% CI, 12.3-21.6) for those with non-long-term response. Baseline Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 (vs. ECOG PS of 1 and ≥ 2) and history of nephrectomy were identified as significant predictors of long-term response to pazopanib.In aRCC patients treated with first-line pazopanib, 22% had a long-term response. Significant predictors of long-term response included an ECOG PS of 0 and a history of nephrectomy.
- Subjects :
- Adult
Male
Oncology
medicine.medical_specialty
Indazoles
Urology
medicine.medical_treatment
Angiogenesis Inhibitors
Disease-Free Survival
Pazopanib
Young Adult
03 medical and health sciences
0302 clinical medicine
Renal cell carcinoma
Internal medicine
medicine
Carcinoma
Humans
In patient
030212 general & internal medicine
Carcinoma, Renal Cell
Aged
Retrospective Studies
Sulfonamides
business.industry
Middle Aged
medicine.disease
Kidney Neoplasms
Confidence interval
Nephrectomy
Long term response
Logistic Models
Pyrimidines
Treatment Outcome
030220 oncology & carcinogenesis
Female
business
Kidney cancer
medicine.drug
Subjects
Details
- ISSN :
- 15587673
- Volume :
- 16
- Database :
- OpenAIRE
- Journal :
- Clinical Genitourinary Cancer
- Accession number :
- edsair.doi.dedup.....0725d07ee27a1946d216650499c55f07
- Full Text :
- https://doi.org/10.1016/j.clgc.2018.03.005